Bracco, Avicenna.AI Win FDA Clearance for AI Aneurysm Tool

Uptunity Aneurysm software helps detect brain aneurysms on cerebral CT angiography images in the United States.

Updated on Nov. 13, 2026 in Artificial Intelligence

Bold flat-color vector editorial illustration of a stylized cluster of tubular branching forms with one coral swelling, evoking a cerebral vascular network.
The FDA cleared Bracco and Avicenna.AI's Uptunity Aneurysm software, which flags suspected brain aneurysms on head CT angiography scans as a concurrent reading aid for clinicians. AI Illustration. Upload story photo >

Bracco and Avicenna.AI have received FDA 510(k) clearance for Uptunity Aneurysm, AI software that detects and assesses brain aneurysms on cerebral CT angiography images. Avicenna.AI will lead promotion and commercial distribution of the product in the U.S.

Why it matters

The clearance allows the software to be marketed in the United States as a concurrent reading aid for clinicians reviewing head CT angiography scans. It is also the first product in Bracco's Uptunity portfolio of interpretive AI software, which was developed through a partnership between Bracco and Avicenna.AI.

Uptunity Aneurysm flags suspected saccular brain aneurysms larger than 3 mm on head CT angiography and, for known aneurysms, provides quantitative measurements and comparisons between exams. Performance statistics such as detection accuracy were not included in the available information.

The players

Bracco

Bracco is a global medical imaging company that develops contrast agents and diagnostic imaging solutions.

Avicenna.AI

Avicenna.AI is a company that develops artificial intelligence software for medical imaging and clinical decision support.

The details

Uptunity Aneurysm reports the presence, location, and size of suspected aneurysms to support radiologists during image review. The clearance was granted through the FDA 510(k) pathway, and the software is intended only as a concurrent reading aid rather than a diagnostic replacement.

Timeline

  1. Clearance of Uptunity Aneurysm by the FDA was reported in an article dated November 13, 2026.

The Tech Race

Uptunity Aneurysm enters a field where AI imaging tools are increasingly cleared through the FDA 510(k) pathway to assist radiologists with detection tasks. The clearance positions Bracco and Avicenna.AI alongside other developers competing to add interpretive AI to standard imaging workflows.

For patients undergoing head CT angiography in the U.S., the software may add an automated screening layer that helps flag aneurysms for radiologist review. Whether it is available at a given hospital will depend on local adoption by providers.

The takeaway

AI tools cleared by the FDA are designed to support, not replace, radiologists, so patients should continue to follow their clinician's guidance on imaging results. Reviewing how a hospital uses AI in its imaging workflow can help clarify what role these tools play in a given diagnosis.

Further reading

For more on how interpretive tools are reshaping medical imaging, explore our coverage of Artificial Intelligence.